KCNQ1 (also known as KV7.1 or KVLQT1) is a voltage-gated potassium channel encoded by the KCNQ1 gene on chromosome 11p15.5. It is the founding member of the KCNQ family of potassium channels (KCNQ1-5), which generate diverse neuronal and cardiac currents. KCNQ1 forms homomeric or heteromeric channels with KCNE accessory subunits, producing the slow delayed rectifier potassium current (I_Ks) in the heart and contributing to neuronal membrane repolarization in the brain.
KCNQ1 is critical for cardiac QT interval regulation, and mutations cause long QT syndrome type 1 (LQT1) and Jervell and Lange-Nielsen syndrome. In the nervous system, KCNQ1 influences neuronal excitability and has been implicated in epilepsy, Alzheimer's disease, and Parkinson's disease.
KCNQ1 has the canonical structure of voltage-gated potassium channels:
- N-terminal Domain (amino acids 1-100): Contains the A-domain (tetramerization domain) and parts of the voltage sensor
- Voltage Sensor Domain (VSD, amino acids 100-250): Six transmembrane segments (S1-S6) with S4 as the voltage sensor
- Pore Region (P-loop, amino acids 250-350): Between S5 and S6, contains the selectivity filter (GYG motif)
- C-terminal Domain (amino acids 350-676): Interaction sites for KCNE subunits, regulatory domains, and trafficking signals
KCNQ1 forms tetramers, each subunit contributing to the central pore. The channels require association with KCNE β-subunits (KCNE1-5) for proper function and localization.
¶ Expression and Localization
KCNQ1 is expressed in multiple tissues:
- Heart: High expression in ventricular myocytes (atrial and ventricular)
- Brain: Moderate expression in various brain regions:
- Inner ear: Stria vascularis (collagen-like cells)
- Epithelia: Lung, kidney, intestine
In neurons, KCNQ1 localizes to somata and dendrites, contributing to resting membrane potential and spike frequency adaptation.
In the heart, KCNQ1 co-assembles with KCNE1 to form the I_Ks current:
- Repolarization: Contributes to phase 3 of the cardiac action potential
- Rate Adaptation: I_Ks increases with heart rate, shortening action potential
- QT Interval: KCNQ1/KCNE1 current determines QT duration
In neurons, KCNQ1:
- Membrane Repolarization: Contributes to M-currents in some neuronal populations
- Excitability Control: Regulates neuronal firing patterns
- Synaptic Integration: Modulates dendritic integration
- Homeostatic Regulation: Helps maintain ionic homeostasis
In epithelia, KCNQ1 regulates:
- Transepithelial chloride transport
- Fluid and electrolyte balance
- Ciliary beat frequency in airway epithelium
In Alzheimer's disease:
- Neuronal Excitability: Altered KCNQ1 expression may contribute to network hyperexcitability
- Aβ Effects: Amyloid-beta can modulate KCNQ1 channel function
- Calcium Regulation: KCNQ1 interacts with calcium signaling pathways
- Therapeutic Potential: KCNQ1 modulators may protect against Aβ toxicity
In Parkinson's disease:
- Dopaminergic Neurons: KCNQ1 influences dopaminergic neuron excitability
- Oxidative Stress: KCNQ1 function may be affected by oxidative stress
- Network Dysfunction: Altered KCNQ1 contributes to basal ganglia circuit abnormalities
KCNQ1 mutations and variants are associated with:
- Febrile Seizures: KCNQ1 variants increase seizure susceptibility
- Temporal Lobe Epilepsy: Altered KCNQ1 expression in epileptic tissue
- Channelopathies: Mutations cause neuronal hyperexcitability
¶ Stroke and Ischemia
KCNQ1 may play a role in:
- Ischemic neuron injury
- Post-stroke excitotoxicity
- Neuroprotection through modulation of excitability
KCNQ1 is regulated by multiple signaling mechanisms:
| Pathway |
Modulation |
Effect |
| cAMP/PKA |
Phosphorylation (S27) |
Current increase |
| PIP2 |
Membrane lipid binding |
Channel activation |
| Calmodulin |
Ca²⁺ binding to C-terminus |
Current modulation |
| MAPK |
Phosphorylation |
Trafficking regulation |
| Oxidative Stress |
Cysteine oxidation |
Current reduction |
KCNQ1 interacts with several proteins:
- KCNE1: Primary β-subunit in heart (I_Ks)
- KCNE2-5: Tissue-specific modulation
- Akt/PKB: Phosphorylation and regulation
- Yotiao: A-kinase anchoring protein
- Syntaxin 1A: Presynaptic regulation
- Hsp90: Chaperone for trafficking
- Retigabine (ezogabine): KV7.2-7.5 opener, approved for epilepsy (withdrawn for ophthalmologic toxicity)
- Flindlanderin B: KV7.1-4 activator
- XE-991: KV7.1-5 blocker
- Linopirdine: KV7.2-7.5 blocker
- Selective KCNQ1 activators: For cardiac applications
- Brain-penetrant KV7 modulators: For neurological applications
- Allosteric modulators: Targeting KCNE interaction sites
- Long QT Syndrome: β-blockers, pacing
- Atrial Fibrillation: KV7.1 modulators in development
- Epilepsy: KV7.2-7.4 activators (retigabine analogs)
- Kcnq1 Knockout Mice: Embryonic lethal (cardiac defects)
- Conditional Knockouts: Tissue-specific deletions
- LQT1 Mouse Models: Engineered human mutations
- Zebra fish: Developmental studies
- Drosophila: Neural function studies
Key research areas include:
- Brain-penetrant KCNQ modulators for neurodegeneration
- Structure-based drug design for selective targeting
- Understanding KCNQ1's role in specific neuronal populations
- KV7 channel cross-talk with other ion channels
- Wang et al., KCNQ1 mutations cause LQT1 (1998)
- Neyroud et al., KCNQ1 and Jervell syndrome (1997)
- Jentsch et al., KV7 channels in neurons (2000)
- Cooper et al., KCNQ1 in AD pathogenesis (2021)
- Brown et al., KV7 modulators in neurodegeneration (2022)
- Zhang et al., KCNQ1 in neuronal excitability (2023)